Age, gender, and racial differences in incidence and survival in primary CNS lymphoma.

Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ. · 2011

Read Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. by Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ. (2011) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3241537.txt.

Introduction

J. L. Villano and colleagues analyzed three decades of United States registry data on primary central nervous system lymphoma, in this 2011 paper in the British Journal of Cancer. This rare lymphoma arises in the brain and related sites without disease elsewhere. Using the national SEER datasets for 1980 to 2008, they tracked incidence and survival by age, sex, and race.

Overall the disease stayed rare, affecting well under one person in a hundred thousand each year, and struck men more than women. Incidence dipped in the late nineteen-nineties, then rose slightly, with the sharpest climb in people over seventy-five. Among younger patients, incidence ran higher in Black than in white Americans, while the pattern reversed at older ages. Five-year survival favored white patients in the younger group, driven by white women. The authors stress that survival remains poor overall.

Catalog record

CREATORVillano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ.
YEAR2011
COLLECTIONPAPERS
FORMATTXT
FILE SIZE26 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC3241537

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Age, gender, and racial differences in incidence and survival in primary CNS lymphoma By J L Villano, M Koshy, H Shaikh, T A Dolecek, B J McCarthy Published in: British Journal of Cancer DOI: 10.1038/bjc.2011.357 ABSTRACT Abstract Background: Primary central nervous system lymphoma (PCNSL) is a rare subtype of extranodal non-Hodgkin lymphoma that accounts for ∼4% of newly diagnosed central nervous system (CNS) tumours. The objective of this study was to analyse the epidemiology, incidence, and outcome of these rare tumours. Methods: Primary brain and CNS lymphoma cases were identified from the Surveillance, Epidemiology, and End Results (SEER) research data sets for the years 1980–2008 for analysis of trends in incidence and survival. SEER*Stat v. 7.0.4 software was used to analyse the data. Results: The overall incidence rate of PCNSL was 0.47 per 100 000 person-years. The incidence was significantly higher in males compared with females, blacks aged 0–49 years at diagnosis compared with whites, and whites aged 50 years and older at diagnosis compared with blacks. After a significant decline in incidence between 1995 and 1999, incidence rates rose slightly; those aged 75+ years at diagnosis had the most dramatic increase in incidence rates over time. Five-year survival rates were significantly higher in whites compared with blacks aged 0–49 years at diagnosis, but was primarily driven by white women aged 0–49 years. Conclusion: There is an increase in incidence of PCNSL in the elderly, and elderly blacks have lower incidence compared with white population. Survival remains poor and is negatively dominated by factors associated with HIV infection and advanced age. Keywords: Lymphoma, brain tumour, epidemiology, incidence, trends Primary central nervous system lymphoma (PCNSL) is a rare disease that accounts for approximately 3–4% of newly diagnosed central nervous system (CNS) tumours (Hoffman et al, 2006). PCNSL is an uncommon subtype of extranodal non-Hodgkin lymphoma that involves the brain, leptomeninges, eyes, or spinal cord without evidence of systemic disease. The majority of PCNSL tumours are of the highly aggressive diffuse large cell subtypes, usually of B-cell phenotypic origin (Miller et al, 1994; Krogh-Jensen et al, 1995; Montesinos-Rongen et al, 2008). The World Health Organization classification of lymphoid and haematopoietic tissue tumours does not recognise PCNSL as a separate entity, as they are indistinguishable morphologically from systemic diffuse large B-cell lymphoma (DLBCL) (Campo et al, 2008). The age-adjusted incidence rate has previously been reported at four cases per million persons per year, or ∼1200 cases per year in the United States (Hoffman et al, 2006). A prominent risk factor for the development of PCNSL is immunodeficiency, which includes congenital disorders, iatrogenic immunosuppression, and most notably, HIV. PCNSL is one of the four AIDS-defining malignancies and HIV infection carries a 3600-fold increased risk of developing the disease compared with the general population (Cote et al, 1996). There has been a significant increase in the incidence of PCNSL from the 1960s, which peaked in the mid-1990s (Schabet, 1999; Olson et al, 2002; Haldorsen et al, 2007). This is generally attributed to the increased incidence of HIV/AIDS and the subsequent development of effective anti-retroviral therapies. There also seems to be an increase in incidence of non-HIV-related PCNSL, which is associated with advanced age (Olson et al, 2002; Norden et al, 2011). Accurate differentiation, however, on a population basis from HIV/AIDS cases can be difficult, especially data sets early in the HIV infection history (1980–90s). Improved imaging and neurosurgical diagnostic services are also likely contributors to increased incidence (Abrey, 2009). The outcome of PCNSL patients is dismal compared with patients with systemic DLBCL, where greater than 50% are long-term survivors. It is unclear if this is attributable to an intrinsic aggressive biological behaviour, the relatively immune-privileged CNS location or to some other yet undetermined cause. Outcomes are also different in HIV/AIDS-related PCNSL having a median survival of 2 months vs a year for non-HIV-related PCNSL (Norden et al, 2011). We used the Surveillance, Epidemiology, and End Results (SEER) Programme of the National Cancer Institute to analyse the epidemiology and outcome of PCNSL, regardless of HIV status. Our goal was to perform a comprehensive analysis on this rare but very deadly brain cancer and relate our findings with systemic lymphomas, which is increasing in incidence in the elderly. We demonstrate that similar to systemic lymphomas there is a clear increase in incidence of PCNSL in the elderly and this increase is enlarging over time. MATERIALS AND METHODS The SEER programme has collected population-based incidence and survival data on all primary malignant cancers since 1973. For both the descriptive incidence data and the survival analyses, the SEER April 2011 research data for 17 registries were used to analyse data for all primary brain and CNS lymphomas diagnosed between 2000 and 2008 (SEER, 2011b, 2011c). The SEER April 2011 research data for nine registries were used to analyse trends in incidence data for all primary brain and CNS lymphomas diagnosed between 1980 and 2008 (SEER, 2011a). The set of ‘all primary malignant brain tumours’ was defined by using the International Classification of Diseases for Oncology (ICD-O-3) site codes of C70.0—C72.9 and C75.1—C75.3, and a behaviour code of 3 (i.e., malignant; Fritz, 2000). Lymphomas were selected using ICD-O-3 histology codes 9590–9599 and 9670–9729. Incidence rates and frequencies were estimated using SEER*Stat v. 7.0.4 (Surveillance Research Program, 2010). Incidence rates were generated for all brain lymphomas overall and by age groups, race, gender, and by diagnosis year to show trends over time. Rates were per 100 000 person-years (p-y) and were age-adjusted to the year 2000 US standard population. Relative survival rates were estimated from the SEER 17-registries research data set using SEER*Stat v. 7.0.4. Relative survival was defined as the observed probability of survival adjusted for the expected survival rate of the US population for that age, sex, and race. Kaplan–Meier relative survival rates were calculated by gender and race group. Survival time was calculated from the date of diagnosis to the date of death or last contact. Patients who were alive were censored at the date of last contact. A Z-score was calculated to compare two survival curves using SEER*Stat v. 7.0.4 and from which a P-value was then estimated (Brown, 1983). Effects of age, sex, and race on PCNSL survival time within two selected age groups (0–49 years and 50+ years) were analysed using proportional hazards regression models (Hosmer et al, 2008). The SEER*Stat Joinpoint Regression Program v. 3.4.3 was used to identify changes in the slope of the lines in incidence rate trends over time using permutation rates in a log linear model (Kim et al, 2000; Montesinos-Rongen et al, 2008). A maximum of three joinpoints were allowed for the number of years included in the analysis. RESULTS The SEER 17 registries research data set comprised 3100 cases of PCNSL diagnosed between 2000 and 2008 (Table 1). The most frequently reported primary sites were the brain lobes (33%) and brain, NOS (not otherwise specified; 34% data not shown). The overall incidence of CNS PCNSL was 0.47 per 100 000 p-y (Table 1), with a significantly higher incidence in males (0.55 per 100 000 p-y) compared with females (0.39 per 100 000 p-y). Incidence rates increased with increasing age at diagnosis (Table 1), and demonstrated a similar pattern

Read the complete text